Q-omics provides the consensus-scored LINC01659 profile across patient tissues and cancer cell-line models. LINC01659 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC01659 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LINC01659 RNA expression shows 16,126 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where LINC01659 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01659 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01659 survival associations across molecular data types. LINC01659 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01659 RNA expression–survival associations across cancer types. High LINC01659 expression shows unfavorable associations in UVM, LGG and CESC, but favorable associations in OV, KIRC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC01659 RNA expression.
This table summarizes LINC01659 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01659. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01659 shows lower tumor expression in KIRC, THCA, KICH and BRCA and higher tumor expression in LUAD and LIHC. The KIRC box plot shows higher LINC01659 RNA expression in normal versus tumor tissue (log2 FC = −1.146, t-test p < 0.001).
This table shows molecular features associated with LINC01659 in patient tissues and cancer cell lines. In patient samples, LINC01659 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
